Short answer
Alnylam Pharmaceuticals (ALNY) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.5B (up 16.7% year over year) with net income of $2.2B.
Q3 2026 key financials · XBRL
- Revenue
- $1.5B
- +16.7% YoY · −40.7% QoQ
- Net income
- $2.2B
- +763.2% YoY · +485.0% QoQ
- Operating margin
- 23.7%
- EPS (diluted)
- $15.71
- +726.8% YoY · +479.7% QoQ
Source: XBRL data from the Alnylam Pharmaceuticals (ALNY) Q3 2026 10-Q on SEC EDGAR. USD.
Alnylam Pharmaceuticals Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $1.458B, up from $1.249B YoY, a $209.1M increase
- Operating margin 23.7% vs 29.5% YoY, net income $2.167B vs $292.7M
- Best performer AMVUTTRA: $1.130B revenue vs $685.3M, up $445.1M
- Worst performer ONPATTRO: $19.6M revenue vs $39.1M, down $19.5M
- Nine-month operating cash flow $738.2M vs $306.4M, with $700.7M used in investing activities
Risk Factors
- New regulatory risk: October 2025 subpoena on government price reporting for four products, with U.S. Attorney engagement continuing
- New legal risk: Cipla’s September 2026 lawsuit challenging AMVUTTRA patents through an FDA generic application
- Operational risk: AMVUTTRA generic competition could affect product sales following Cipla’s abbreviated new drug application
- Financial risk: $362.8 million of 2027 convertible notes classified current, maturing September 15, 2027
- Collaboration risk: Regeneron’s Initial Research Term expired in May 2026, ending exclusivity for new eye and CNS discovery programs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Alnylam Pharmaceuticals quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.